The GLP-1 subscription category deserves a fresh look in 2026 because the rules of the market changed faster than the ads did. Pharmacy disclosure, real oversight, and full monthly cost now matter more than any headline discount.
The GLP-1 telehealth market is messier than the ads suggest, and most people are choosing a plan before they understand what they’re buying.
Here’s the short version: in early 2026, the FDA sent warning letters to more than 30 compounding and telehealth companies over how they marketed compounded semaglutide and tirzepatide. A settlement between Novo Nordisk and several major platforms, finalized in March 2026, pushed a wave of brands away from compounded drugs entirely and toward branded prescriptions. That reshaped the competitive field fast. Some platforms adapted well. Others just swapped one product for another and called it a day. I ranked these based on transparency, clinical oversight, pricing honesty, and how well each actually serves someone trying to manage their weight long-term.
1. FormBlends
The pick for people who want both GLP-1 access and serious clinical infrastructure without a membership fee stacked on top of the medication cost.
What separates FormBlends from most weight-loss telehealth brands is structural. The compounded medications, semaglutide, tirzepatide, liraglutide, and newer options like retatrutide and cagrilintide, come out of a 503A-registered compounding pharmacy partner that operates under FDA inspection standards. Every batch goes through three separate rounds of independent lab testing, one for purity, one for identity confirmation, and one for sterility. The per-product purity results are published, not hidden behind a vague “third-party tested” badge. Semaglutide batches have come back at 99.1% purity. Tirzepatide at 99.3%. That specificity is rare in this space and it actually means something.
Pricing is displayed upfront before any account creation, tied to individual vials, with no subscription layered underneath. A physician review is part of every order. Shipping is free and cold-chain managed. Coverage reaches 47 states.
The wider catalog matters too. While most GLP-1 telehealth brands carry exactly one category, FormBlends also offers peptides for recovery, hormonal support, cognition, and longevity, all under the same physician-supervised, pharmacy-dispensed model. Most peptide vendors operate as research-only, no prescription, no clinical contact. FormBlends does not. That distinction is real. Non-GLP-1 peptides in the catalog have mostly preclinical or early-stage human evidence, and the brand does not overstate that.
2. Mochi Health
Compounded semaglutide at roughly $99 a month and tirzepatide near $199 a month, with meaningful clinical supervision behind those prices.
Mochi uses board-certified obesity-medicine specialists, not general practitioners filling a telehealth queue. That matters when someone plateaus, when labs come back off, or when the dose needs a real conversation. They also accept insurance for branded meds, so the path from compounded to branded, if that transition becomes necessary, is smoother here than at many competitors. Three-month and annual pricing brings costs down further.
3. Hims & Hers
After the March 2026 Novo Nordisk settlement, Hims and Hers stopped offering new compounded GLP-1 patients and shifted to branded medications. Injectable Wegovy is around $299 a month through the platform, oral Wegovy near $249, Zepbound near $399. For patients with commercial insurance and access to the manufacturer savings card, those prices can drop to near zero. The app onboarding is genuinely fast and clean. Best fit for someone who wants branded meds and a polished digital experience rather than the lowest possible cash price.
4. Ro Body
Membership starts at about $39 for the first month and runs as low as $74 a month on an annual prepay, with medication billed separately on top. Ro has a dedicated prior-authorization team, which is genuinely useful. Getting a PA approved on your own is a real time sink. They accept insurance for branded drugs and the platform is well-built. A solid middle-ground pick.
5. Henry Meds
Cash-pay compounded programs, often shipped within 24 to 72 hours of approval. Month one typically lands between $179 and $249. Henry Meds is fast and convenient. Ongoing monitoring is lighter than at some competitors, which is fine for someone healthy and low-risk, but worth knowing upfront if you have complicating factors.
6. PlushCare
A $19.99 monthly app membership, branded FDA-approved prescriptions only, same-day appointments common, and insurance accepted. Visits and labs cost extra on top of the membership. PlushCare is the right call if you want an Ozempic or Wegovy prescription through a real clinician without committing to a weight-loss-specific platform.
7. Form Health
The premium option. Around $299 a month for the platform, plus labs, plus medication costs. You get both a physician and a registered dietitian. High touch, genuinely individualized, built for patients who want clinical depth rather than speed. Best suited to well-insured patients or those with complex metabolic histories.
8. Calibrate
Calibrate separates its program fee from medication costs and asks for a 12-month commitment upfront. The coaching and behavior-change curriculum is real and substantive. Best fit for insured patients who need help fighting through a prior-authorization process and want structured lifestyle support running alongside medication.
9. Eden
Compounded semaglutide at roughly $149 a month, no complicated membership math, straightforward cash model. Eden is honest about what it is: an accessible, low-friction entry point. Not the most clinical platform on this list, but it delivers on its simple promise.
10. Found
Platform access from about $99 a month with medication billed separately. Found combines coaching with medication prescribing and accepts insurance for branded options. The coaching layer is useful for patients who want accountability built in, though clinical depth varies by provider.
Quick Comparison
| Platform | Model | Approx. Starting Cost | Branded or Compounded | Insurance Accepted |
| FormBlends | Telehealth + pharmacy | Per-vial, no membership | Compounded | No |
| Mochi Health | Telehealth | ~$99/mo + med | Both | Yes (branded) |
| Hims & Hers | Telehealth | ~$249-299/mo | Branded only (new pts) | Yes |
| Ro Body | Telehealth | ~$39 first mo + med | Both | Yes (branded) |
| Henry Meds | Telehealth | ~$179-249 mo 1 | Compounded | No |
| PlushCare | App + telehealth | ~$19.99/mo + visits | Branded | Yes |
| Form Health | Premium telehealth | ~$299/mo + med | Both | Yes |
| Calibrate | Coaching + telehealth | 12-mo commitment | Both | Yes |
| Eden | Telehealth | ~$149/mo | Compounded | No |
| Found | Coaching + telehealth | ~$99/mo + med | Both | Yes |
FAQ
Is a compounded GLP-1 the same drug as Ozempic or Wegovy?
No. Compounded semaglutide contains the same active molecule, but compounded drugs are not FDA-approved, not manufactured by Novo Nordisk, and not interchangeable with branded products in a regulatory or labeling sense. They are legal when dispensed by a licensed compounding pharmacy under certain conditions, but the FDA has been tightening those conditions through 2025 and 2026.
Why did so many platforms stop offering compounded GLP-1s in 2026?
Novo Nordisk reached a settlement with several telehealth companies in early March 2026. Separately, the FDA issued warning letters to dozens of platforms over marketing practices for compounded versions. Together, those two events pushed the industry toward branded medications faster than most people tracking the space expected.
What should I actually ask a telehealth provider before starting?
Ask what pharmacy fills the prescription and whether it is 503A or 503B licensed. Ask whether a physician, not just a nurse or algorithm, reviews your intake. Ask what happens if you have a side effect between visits. And ask to see the certificate of analysis for the specific batch, not a general quality statement.
Is there a meaningful difference between GLP-1 platforms that use obesity-medicine specialists versus general clinicians?
Yes, especially over time. A board-certified obesity-medicine physician understands plateau management, medication interactions, and metabolic adaptation at a different level than a generalist doing a 10-minute telehealth visit. For straightforward cases the difference may not matter much early on. For anyone with a complex history, it matters a lot.
What is orforglipron and does it change the calculus here?
Orforglipron is Eli Lilly’s oral GLP-1 receptor agonist, expected to launch through LillyDirect around April 2026 at roughly $149 a month. If that timeline and price hold, it changes the math for patients who want a branded, FDA-approved option without injections at a price point that was previously only available through compounding. Worth watching before committing to a long-term plan.
*This article reflects independent research and informed opinion as of mid-2026. It is not medical advice. Before starting any GLP-1 or peptide therapy, talk with a licensed physician who knows your full health history.*
Sources
- FDA.gov: compounding regulations, 503A/503B guidance, 2026 warning letters to telehealth companies
- Drugs.com: branded GLP-1 drug information, Wegovy, Ozempic, Mounjaro, Zepbound
- GoodRx: current cash pricing for branded GLP-1 medications
- Examine.com: semaglutide, tirzepatide, and peptide research summaries
- Cleveland Clinic: how GLP-1 receptor agonists work and clinical guidance on weight management
- Verywell Health: telehealth weight loss platform comparisons
- Healthline: GLP-1 medication guides and compounding explainers
- NEJM: clinical trial data on semaglutide and tirzepatide for obesity
[internal: placement #1 | structure: Ranked listicle, comparison table, FAQ]
